Mariangela Giunta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mariangela Giunta has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Davide Ravizza
Division of Endoscopy, European Institute of Oncology, IRCCS, Milan, Italy
2 shared publications - Mirella Fraquelli
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
2 shared publications - Antonio Nicolini
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, UOC Radiologia, Milan, Italy
1 shared publication - Clara Benedetta Conti
Gastroenterology and Digestive Endoscopy Unit, ASST Cremona, Cremona, Italy
1 shared publication - Cristiano Crosta
European Institute of Oncology, Milan, Italy
1 shared publication Cristina Trovato
Division of Endoscopy European Institute of Oncology, IRCCS Milan Italy
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Breaking the Size Barrier: Endoscopic Submucosal Dissection of a Massive Flat Gastric Neuroendocrine Tumor
Type I gastric neuroendocrine tumors, arising in chronic atrophic gastritis, are usually small, mucosal, or submucosal elevated lesions. Current guidelines recommend endoscopic resection of lesions ≤20 mm and surgical treatment for those >20 mm. We report an unusual case of a 56-year-old woman with a completely flat (Paris 0-IIb) gastric body neuroendocrine tumor (NET) measuring 140 × 35 mm, detected by virtual chromoendoscopy and successfully resected by endoscopic submucosal dissection without complications. Histology revealed about 40 well-differentiated low-grade NET foci. After 6 months, no recurrence occurred, confirming endoscopic submucosal dissections curative potential in this exceptional giant but flat NET case.
- 1 July 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Open AccessBreaking the Size Barrier: Endoscopic Submucosal Dissection of a Massive Flat Gastric Neuroendocrine Tumor
Type I gastric neuroendocrine tumors, arising in chronic atrophic gastritis, are usually small, mucosal, or submucosal elevated lesions. Current guidelines recommend endoscopic resection of lesions ≤20 mm and surgical treatment for those >20 mm. We report an unusual case of a 56-year-old woman with a completely flat (Paris 0-IIb) gastric body neuroendocrine tumor (NET) measuring 140 × 35 mm, detected by virtual chromoendoscopy and successfully resected by endoscopic submucosal dissection without complications. Histology revealed about 40 well-differentiated low-grade NET foci. After 6 months, no recurrence occurred, confirming endoscopic submucosal dissections curative potential in this exceptional giant but flat NET case.
- 27 August 2024
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 36 (12) , e13440
Gastric neuroendocrine tumors: 20‐Year experience in a reference center
Few studies have been published on the long‐term outcomes of patients with gastric neuroendocrine tumors (gNETs). We analyzed their management over a two‐decade period, focusing on endoscopic and clinical outcomes. Clinical, laboratory, endoscopic, surgical, and histopathological data from Types 1 and 3 gNETs histologically diagnosed between March 2000 and December 2021 at the European Institute of Oncology (IEO, Milan) were retrospectively collected. Sixty‐nine patients were included (60 Type 1, 9 Type 3): 53 (77%) were treated endoscopically, 6 (9%) surgically, and 10 (14%) did not receive any treatment. Overall, 293 lesions were removed endoscopically: 74% by forceps, 20% by endoscopic mucosal resection (EMR), and 5% by endoscopic submucosal dissection (ESD). No differences were observed between EMR and ESD in terms of complete resection rate (p value = .50) and complications rate (p value = .084). The median follow‐up period was 5.8 years (range: 0.3–20.5), during which no gNET‐related deaths were observed. Metachronous gNETs developed in 60% of patients with Type 1 gNET. Six patients with lymph node metastases (LNM) were younger (p value = .006) and had larger lesions (p value <.001) than patients without LNM. Most Type 1 gNETs were successfully excised using forceps, with EMR and ESD being equally effective. The presence of incomplete resection was not associated with a worse prognosis, which remains excellent in this highly recurrent disease. Younger age and a size ≥10 mm were associated with an increased risk of LNM.Clinical Trial Registration: Project code UID 2854.
- 27 August 2024
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 36 (12) , e13440
Gastric neuroendocrine tumors: 20‐Year experience in a reference center
Few studies have been published on the long‐term outcomes of patients with gastric neuroendocrine tumors (gNETs). We analyzed their management over a two‐decade period, focusing on endoscopic and clinical outcomes. Clinical, laboratory, endoscopic, surgical, and histopathological data from Types 1 and 3 gNETs histologically diagnosed between March 2000 and December 2021 at the European Institute of Oncology (IEO, Milan) were retrospectively collected. Sixty‐nine patients were included (60 Type 1, 9 Type 3): 53 (77%) were treated endoscopically, 6 (9%) surgically, and 10 (14%) did not receive any treatment. Overall, 293 lesions were removed endoscopically: 74% by forceps, 20% by endoscopic mucosal resection (EMR), and 5% by endoscopic submucosal dissection (ESD). No differences were observed between EMR and ESD in terms of complete resection rate (p value = .50) and complications rate (p value = .084). The median follow‐up period was 5.8 years (range: 0.3–20.5), during which no gNET‐related deaths were observed. Metachronous gNETs developed in 60% of patients with Type 1 gNET. Six patients with lymph node metastases (LNM) were younger (p value = .006) and had larger lesions (p value <.001) than patients without LNM. Most Type 1 gNETs were successfully excised using forceps, with EMR and ESD being equally effective. The presence of incomplete resection was not associated with a worse prognosis, which remains excellent in this highly recurrent disease. Younger age and a size ≥10 mm were associated with an increased risk of LNM.Clinical Trial Registration: Project code UID 2854.
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S191
Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignances: a single center experience
Aims to assess the feasibility, safety and efficacy of partially covered self-expandable metal stents (PC SEMS) for leaks after esophageal or gastric resection for malignances Methods we retrospectively collected data of patients from November 2018 to October 2022 Results 23 patients (18 M, median age 70 yrs) were included. 11 patients had an esophagogastric anastomosis, 11 an esophagojejunal anastomosis and 1 an esophago-colonic anastomosis. 22 defects were anastomotic leak, 1 was a leak of the jejunal cul-de-sac. The median time between surgery and leak diagnosis was 8 (3-44) days. 20 (87 %) patients received Boston Ultraflex partially covered stent (100/120/150 mmx18/23 mm) and 3 (13 %) patients Boston Agile partially covered stent (120/150x23 mm). Stent placement was technically successful in all patients. The median time between stent placement and removal was 29 (4-52) days. One patient died for other causes with stent in place. PC SEMS retrieval was safe and easy, except for one patient who needed stent-in-stent technique for the subsequent successful removal. 15/22 and 2/22 patients obtained leak resolution after one and two stent placement respectively, with an overall success rate of 77%. Concerning patients with persistent leak, 1 patient achieved defect healing with Esosponge, 4 (17%) patients needed reintervention. During a median follow-up time of 4.4 (1.1-35.2) months, complications were observed in 4/22 (18%) patients: 2 migrations, 1 stricture at the level of the proximal stent margin, 1 self-limiting haemorrage Conclusions PC SEMS placement is a feasible, safe and effective technique for leak treatment after esophageal or gastric surgery for malignances Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S191
Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignances: a single center experience
Aims to assess the feasibility, safety and efficacy of partially covered self-expandable metal stents (PC SEMS) for leaks after esophageal or gastric resection for malignances Methods we retrospectively collected data of patients from November 2018 to October 2022 Results 23 patients (18 M, median age 70 yrs) were included. 11 patients had an esophagogastric anastomosis, 11 an esophagojejunal anastomosis and 1 an esophago-colonic anastomosis. 22 defects were anastomotic leak, 1 was a leak of the jejunal cul-de-sac. The median time between surgery and leak diagnosis was 8 (3-44) days. 20 (87 %) patients received Boston Ultraflex partially covered stent (100/120/150 mmx18/23 mm) and 3 (13 %) patients Boston Agile partially covered stent (120/150x23 mm). Stent placement was technically successful in all patients. The median time between stent placement and removal was 29 (4-52) days. One patient died for other causes with stent in place. PC SEMS retrieval was safe and easy, except for one patient who needed stent-in-stent technique for the subsequent successful removal. 15/22 and 2/22 patients obtained leak resolution after one and two stent placement respectively, with an overall success rate of 77%. Concerning patients with persistent leak, 1 patient achieved defect healing with Esosponge, 4 (17%) patients needed reintervention. During a median follow-up time of 4.4 (1.1-35.2) months, complications were observed in 4/22 (18%) patients: 2 migrations, 1 stricture at the level of the proximal stent margin, 1 self-limiting haemorrage Conclusions PC SEMS placement is a feasible, safe and effective technique for leak treatment after esophageal or gastric surgery for malignances Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 26 August 2021
- Published by Springer Nature
- p. 257-268
Liver and Spleen Stiffness in Hematological Diseases
- 26 August 2021
- Published by Springer Nature
- p. 257-268
Liver and Spleen Stiffness in Hematological Diseases
- Open Access
- 1 July 2020
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 46 (7) , 1641-1650
The Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function
- 1 July 2020
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 46 (7) , 1641-1650
Open AccessThe Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function